DonCorleone77
Posted - 5 days ago
$TAK $ALPMY $SMFG Takeda, Astellas Pharma and Sumitomo Mitsui form early drug discovery JV Ciconia Bioventures announced its establishment as a joint venture, or JV, company based on a master agreement signed on April 22 by Takeda Pharmaceutical (TAK), Astellas Pharma (ALPMY), and Sumitomo Mitsui Banking Corporation (SMFG). Ciconia covers the entire process from early drug discovery research to establishment of biotech startups, with the aim of translating innovative technologies and drug discovery programs originating in Japan into clinical applications.
justiceforb_85
Posted - 09/29/24
$ELEV do we know how EO-3021 compares with $ALPMY 's zolbetuximab?
jParkz
Posted - 09/24/24
$ALPMY News Japan's Ministry of Health, Labour and Welfare Approves PADCEV(TM) (enfortumab vedotin) with KEYTRUDA (pembrolizumab) for First-Line Treatment of Radically Unresectable Urothelial Carcinoma https://marketwirenews.com/news-releases/japan-s-ministry-of-health-labour-and-welfare-approv-6164404325343182.html $ALPMY
Quantumup
Posted - 09/17/24
Piper Sandler reiterated $RVMD Overweight/$57. $ALPMY's ASP3082🔬@#ESMO reinforces PS's view of RMC-6236's BiC efficacy in G12X PDAC + new🔬@#ESMO for a 5-FU/irinotecan in 2L PDAC further support control arm assumptions for RMC-6236's planned P3/what it sees as a high likelihood of superiority: $pfe $ipsey $amgn
jParkz
Posted - 1 month ago
News out $ALPMY Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 https://marketwirenews.com/news-releases/astellas-presents-scientific-progress-in-advanced-an-8338271271453901.html $ALPMY
LewisDaKat
Posted - 08/19/24
News $ALPMY China's National Medical Products Administration (NMPA) Approves PADCEV(TM) (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer https://marketwirenews.com/news-releases/china-s-national-medical-products-administration-nmp-7683500183499865.html $ALPMY
blackboxlabel
Posted - 2 months ago
$APLS $ALPMY Astellas just posted earnings, in Japan time.
https://www.astellas.com/en/investors/ir-library/business-results
~35% market share.
PenkeTrading
Posted - 07/26/24
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Astellas Pharma Inc. Is that bullish or bearish? $ALPMY #ALPMY #pink #tradingsignals #technicalanalysis
falconfly1
Posted - 3 months ago
$EYEN $LGND and $ALPMY and $LLY and $COEP What is new and opportunity in $EYEN? 1 - Insider bought 1.5 million shares in July and paid 1 Million dollars 2 - Vanguard biggest institution in the world bought 5 million dollars for a call option 3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company. 4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 million per quarter. 5 - 8 or 9 August earnings call, and it should be good. 6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.
Quantumup
Posted - 06/28/24
BofA $APLS Buy/$82 "Negative CHMP for Syfovre was in-line with our expectations" Final opinion expected in 4Q; US remain🔑mkt BofA awaits further color on the progress of review process but reits view — US mkt is the🔑comm opp=$3.6B to its $3.8B risk-adjd peak sales est. $alpmy
DonCorleone77
Posted - 4 months ago
$ALPMY Astellas Pharma's treatment of pancreatic cancer granted FDA orphan designation According to a post on the FDA's website, Astellas Pharma's treatment of pancreatic cancer was granted orphan designation.
Quantumup
Posted - 4 months ago
Cantor Fitzgerald reiterated $BCYC Overweight/$60~after hosting an inv dinner w/ $BCYC team@ #ASCO24 📝interest in radiopharma programs/isotope strategy⬆️; Mgmt reinforced confidence in BT8009/its value proposition vs. Padcev (based on Co updated mkt research/interactions w/ MD's: $alpmy
Quantumup
Posted - 04/30/24
Jefferies view on safety of $APLS ' (Buy$80) Syfovre retinal vasculitis cases remains unchanged; the 2 deaths in FAERS data were not related to Syfovre/Re: RV cases, only 4 of them actually occurred in Q1. Reminds invs, "keep in mind cases reported by the FDA are not adjudicated." $alpmy
Quantumup
Posted - 04/30/24
JPMorgan $APLS Overweight/$79~says, ‘‘Recall The FAERS Database Is NOT Adjudicated, And It Is Dangerous To Over Interpret’’ The 2 deaths speculated by the St are*NOT related to Syfovre (died of natural cases/pts are elderly). FAERS database is*NOT verified/highlighted duplicates: $alpmy
DonCorleone77
Posted - 04/22/24
$TAK $ALPMY $SMFG Takeda, Astellas Pharma and Sumitomo Mitsui to establish joint venture company Takeda (TAK), Astellas Pharma (ALPMY), and Sumitomo Mitsui (SMFG) announced that the three companies signed a master agreement on April 22 to establish a joint venture company. The new company will be dedicated to the incubation of early drug discovery programs, primarily originating from Japan and toward the creation of innovative therapeutics. In addition to establishing the joint venture company, Takeda and Astellas will provide support to the joint venture company leveraging their expertise gained from global drug discovery research and development, aiming to accelerate open innovation in early-stage drug discovery, and toward the creation of start-up companies for the benefit of society. The joint venture company plans to begin incubation activities by collaboratively working with academia, pharmaceutical companies, and start-up companies across Japan to enable access to potentially transformative early drug discovery programs. The three companies will further discuss the details of the agreement to complete the inception of the joint venture company and commence operations, aiming for a swift launch of the new incubation activities.
BiotechJedi1728
Posted - 03/19/24
@Snake2010 $BAYRY is instilling cost savings measures for the company. That frees up dollars for acquisitions. I wouldn’t be surprised if it is in play. 🤷🏻♂️ but there is $OGN and $ALPMY too.
maphere
Posted - 7 months ago
$CLSD $ALPMY Clearside injector included in a new world patent from Astellas: Publication Date 29.02.2024 WO2024044134 - PHOTORECEPTOR RESCUE CELL (PRC) COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISORDERS Applicants ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE [US]/[US] The photoreceptor rescue cells can be administered via a device, for example a syringe, the Oxulumis Illuminated Suprachoroidal Microcatheter (Oxular), P0D3 Gold (Oxular), Oxuspheres (Oxular), SCS microinjector (Clearside Biomedical), Orbit SDS (Gyroscope), via an implant, via a cell seeded substrate or an implantable membrane, either alone or in combination with another cell type, for example retinal pigment epithelial cells. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2024044134&_cid=P10-LTN0YA-81578-1
mojo999
Posted - 02/28/24
$CTMX [PART 2] ⭐EGFRxCD3 T-cell engager initial Phase 1a dose escalation data 2H - IND application filed for conditional approval ⭐Activated EpCAM-directed ADC for EpCAM positive tumors expected in the 1H 2024 ⭐Heavy weight smart $ biotech investors are largest shareholders: BVF, Tang etc ⭐7 ADCs in partnerships with 5 big pharmas:$AMGN, $ALPMY, $BMY, $REGN, $MRNA ⭐Any of large pharma partners could easily take them out a multiples to the current price. Appears grossly undervalued even with recent move. Looks ripe for continued revaluation. https://twitter.com/smantel/status/1762935786306232461
Jnbond7
Posted - 02/22/24
$ALPMY In regards to Veozah, $ALPMY and pharmacies need to get their act together. Pharmacies aren't honoring Veozah-saving cards. It's also difficult to process Veozah through insurance. Veozah is already expensive w/o the need of making things into an administrative nightmare. Probably the reason why $ALPMY is down; if not, all the shenanigans definitely don't help.
DonCorleone77
Posted - 01/30/24
$ALPMY Astellas Pharma announces strategic collaboration with Mass General Brigham Astellas Pharma announced that it has entered into a strategic collaboration with Mass General Brigham that is focused on translational medicine and early development to establish an integrated approach to scientific advancement and clinical expertise. Initial projects of mutual interest will be focused in key areas of R&D investment for Astellas, including oncology, rare disease, and cell and gene therapy. Through the alliance, Astellas and Mass General Brigham aim to: Accelerate innovation through collaborative research, as well as exploring and expanding new research frontiers; translate innovative research into clinical trials and actionable solutions that address serious unmet needs and aim to improve healthcare for all; leverage scientific and clinical expertise to inform and accelerate the development of novel therapies.
DonCorleone77
Posted - 01/26/24
$PFE $ALPMY EMA validates Type II variation application for Padcev-Keytruda combination Pfizer (PFE) and Astellas Pharma (ALPMY) announced that on January 26 the European Medicines Agency validated for review a Type II variation application for PADCEV with KEYTRUDA as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer. If approved, PADCEV with KEYTRUDA has the potential to change the treatment paradigm, becoming the first combination treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC. Globally, approximately 573,000 new cases of bladder cancer and 212,000 deaths are reported annually.1 It is estimated that approximately 200,000 people in Europe are diagnosed with bladder cancer each year.
STCKPRO
Posted - 9 months ago
$ALPMY NEW ARTICLE : US FDA declines to approve Astellas' gastric cancer drug https://www.stck.pro/news/ALPMY/72094444/
STCKPRO
Posted - 9 months ago
$ALPMY NEW ARTICLE : Astellas Provides Update on Zolbetuximab Biologics License Application in U.S. https://www.stck.pro/news/ALPMY/72091874/
DonCorleone77
Posted - 9 months ago
$ALPMY 2 of 2 - FDA says it cannot approve Astellas BLA for zolbetuximab by PDUFA action date ....The FDA stated that the agency cannot approve the BLA by the Prescription Drug User Fee Act (PDUFA) action date of January 12, 2024, due to unresolved deficiencies following its pre-license inspection of a third-party manufacturing facility for zolbetuximab. The FDA has not raised any concerns related to the clinical data, including efficacy or safety, of zolbetuximab, and is not requesting additional clinical studies. Astellas is working closely with the FDA and the third-party manufacturer to establish a timeline to quickly resolve the agency's feedback. No other Astellas products are affected.
DonCorleone77
Posted - 9 months ago
$ALPMY 1 of 2 - FDA says it cannot approve Astellas BLA for zolbetuximab by PDUFA action date Astellas Pharma announced the U.S. Food and Drug Administration (FDA) issued a complete response letter on January 4, 2024, regarding the Biologics License Application (BLA) for zolbetuximab, an investigational agent for the treatment of patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive....
Stock_Titan
Posted - 9 months ago
$ALPMY Astellas Provides Update on Zolbetuximab Biologics License Application in U.S.
NOCTURNALCREATURE
Posted - 9 months ago
$ALPMY why this multi billion company is not even listed on major markets? Ridicolous
BiotechJedi1728
Posted - 9 months ago
$DARE Clown boy thinks a big pipeline is bad. lol 😂 Every product is another asset to out-license or make it an attractive buyout for bigger companies in women’s health like $OGN and $ALPMY He is talking about a cruise. 😆 Sabrina is cornering billion dollar markets 🤦🏻♂️
